Carotid Artery Stenting With Cilostazol Addition for Restenosis

Summary

CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting (CAS) in patients scheduled to undergo CAS. Study design is Multicenter Prospective Ranodomized Controlled Study, rondomized by cilostazol/non-cilostazol group prior to CAS. 900 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after CAS, evaluated by carotid ultrasound and angiography.

Conditions

• In-stent Restenosis After Carotid Artery Stenting

Interventions

DRUG

Cilostazol or Non-Cilostazol

Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.

Sponsors & Collaborators

• Chiba University

  collaborator OTHER

• Nagoya University

  collaborator OTHER

• Mie University

  collaborator OTHER

• Wakayama Medical University

  collaborator OTHER

• Kyoto University

  collaborator OTHER

• Osaka University

  collaborator OTHER

• Kobe University

  collaborator INDUSTRY

• Foundation for Biomedical Research and Innovation

  collaborator OTHER

• Okayama University

  collaborator OTHER

• Yamaguchi University Hospital

  collaborator OTHER

• Fukuoka University

  collaborator OTHER

• Nagasaki University

  collaborator OTHER

• Kobe City General Hospital

  lead OTHER

Principal Investigators

• Nobuyuki Sakai, MD, DMSc · Kobe City Medical Center General Hospital

• Hiroshi Yamagami, MD, PhD · Kobe City Medical Center General Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-12-31

Primary Completion

2019-03-31

Completion

2019-09-30

Countries

• Japan

Study Locations